Efficacy and safety of remitazolam combined with remifentanil in sedation and analgesia in patients with ECMO

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100053180

Enrollment

Unknown

Registered

2021-11-13

Start date

2022-01-01

Completion date

Unknown

Last updated

2022-09-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute respiratory distress syndrome, cardiogenic shock

Interventions

Experimental group:Remazolam combined with remifentanil combined with sedation and analgesia

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: Patients admitted to the ICU with endotracheal intubation and mechanical ventilation and ECMO support.

Exclusion criteria

Exclusion criteria: 1. Patients who were forced to be weaned off due to serious complications of ECMO treatment; 2. Patients with hepatic insufficiency before enrollment; 3. Pregnant patients and children; 4. Patients receiving ECMO treatment for more than 7 days; 5. Those with previous liver basic diseases such as hepatitis and liver cirrhosis; 6. Patients who have been sedated with midazolam.

Design outcomes

Primary

Measure	Time frame
Hemodynamic status;Bispectral index (BIS);	—

Countries

China

Contacts

Public ContactLi Tianlong

Sichuan Academy of Medical Sciences (Sichuan Provincial People's Hospital)

ajay1989@126.com+86 18782094080

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026